Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Characterizing the Collateral Activity of CRISPR/Cas13 in Mammalian Cells: Implications for RNA Editing and Therapeutic Applications

ABSTRACT: The CRISPR/Cas13 system has garnered attention as a potential tool for RNA editing. However, the degree of collateral activity among various Cas13 orthologs and their cytotoxic effects in mammalian cells remain contentious, potentially impacting their applications. In this study, we observed differential collateral activities for LwaCas13a and RfxCas13d in 293T and U87 cells by applying both sensitive dual-fluorescence (mRuby/GFP) reporter and quantifiable dual-luciferase (Fluc/Rluc) reporter, with LwaCas13a displaying notable activity contrary to previous reports. However, significant collateral RNA cleavage exerted only a modest impact on cell viability. Furthermore, the collateral activity of LwaCas13a mildly impeded but did not arrest, porcine embryo development. Our findings reveal that distinct collateral RNA cleavage by Cas13 slightly suppresses mammalian cell proliferation and embryo development. This could account for the lack of reported collateral effects in numerous prior studies and offers new insights into the implications of the collateral activity of Cas13 for clinical application.

ORGANISM(S): Homo sapiens

PROVIDER: GSE254168 | GEO | 2024/01/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects

Project description:We found that several variants with 2-4 mutations on Higher Eukaryotes and Prokaryotes Nucleotide-binding (HEPN) domains showed undiminished on-target activity but markedly reduced collateral effects. Furthermore, transcriptome-wide off-target effects and cell growth arrest induced by wild-type Cas13d were found to be absent for a Cas13d variant. Thus, high-fidelity Cas13 variants with minimal collateral effects are now available for the targeted degradation of RNAs in basic research and therapeutic applications.

2022-06-28 | GSE168246 | GEO

Intrinsic RNA targeting constrains the utility of CRISPR-Cas13 systems [Screen]

Project description:CRISPR-Cas13 systems have been adapted as versatile toolkits for RNA-related applications. Here we systematically evaluate the performance of several prominent Cas13 family effectors (Cas13a, Cas13b and Cas13d) under lentiviral vectors and reveal surprisingly differential defects and characteristics of these systems. Using RNA immunoprecipitation sequencing, transcriptome profiling, biochemistry analysis and high-throughput CRISPR-Cas13 screening approaches, we determine that each Cas13 system has its intrinsic RNA targets in mammalian cells. Viral process-related host genes can be targeted by Cas13 and affect the production of fertile lentiviral particles, thereby restricting the utility of lentiviral Cas13 systems. Multiple RNase activities of Cas13 are involved in endogenous RNA targeting. Unlike target-induced collateral effect, intrinsic RNA targeting can be specific, target-independent and dynamically tuned by varied states of Cas13 nucleases. Our work not only provides guidance to appropriately utilize lentiviral Cas13 systems, but also raises cautions about intrinsic RNA targeting during Cas13-based basic and therapeutic applications.

2023-10-09 | GSE202841 | GEO

Intrinsic RNA targeting constrains the utility of CRISPR-Cas13 systems [RIP-seq]

2023-10-09 | GSE202898 | GEO

Intrinsic RNA targeting constrains the utility of CRISPR-Cas13 systems [RNA-seq]

2023-10-09 | GSE202838 | GEO

Transcriptome changes upon Cas13-based knockdown

Project description:We used RNA-seq to detect genome-wide gene expression change when a reporter RNA was targeted by Cas13

2023-02-24 | GSE155134 | GEO

Negative autoregulation mitigates collateral RNase activity of repeat-targeting CRISPR-Cas13d in mammalian cells

Project description:Cas13 is a unique family of CRISPR endonucleases exhibiting programmable binding and cleavage of RNAs and is a strong candidate for eukaryotic RNA knockdown in the laboratory and the clinic. However, sequence-specific binding of Cas13 to the target RNA unleashes non-specific bystander RNA cleavage, or collateral activity, which may confound knockdown experiments and raises concerns for therapeutic applications. Although conserved across orthologs and robust in cell-free and bacterial environments, the extent of collateral activity in mammalian cells remains disputed. Here, we investigate Cas13d collateral activity in the context of an RNA-targeting therapy for myotonic dystrophy type 1, a disease caused by a transcribed long CTG repeat expansion. We find that when targeting CUGn RNA in HeLa and other cell lines, Cas13d depletes endogenous and transgenic RNAs, interferes with critical cellular processes, and activates stress response and apoptosis pathways. We also observe collateral effects when targeting other repetitive and unique transgenic sequences, and we provide evidence for collateral activity when targeting highly expressed endogenous transcripts. To minimize collateral activity for repeat-targeting Cas13d therapeutics, we introduce gRNA excision for negative-autoregulatory optimization (GENO), a simple strategy that leverages crRNA processing to control Cas13d expression and is easily integrated into an AAV gene therapy. We argue that thorough assessment of collateral activity is necessary when applying Cas13d in mammalian cells and that implementation of GENO illustrates the advantages of compact and universally robust regulatory systems for Cas-based gene therapies.

2021-12-23 | GSE191329 | GEO

Next-generation sequencing facilitates transcriptomes quantitative analysis of stably expressing RfxCas13d HEK293T cells transfected with target genes and corresponding crRNAs

Project description:To determine what effect the collateral activity of RfxCas13d has on cells, a HEK293T cell line stably expressing RfxCas13d (HEK293T-RfxCas13d) was constructed and then transfected with plasmids encoding target gene and corresponding crRNAs. After 24 hours of transfection, cells were collected and extracted for total RNA. Then, we performed RNA-seq to compare the differentially expressed genes between cells transfected with targeting crRNAs and non-targeting crRNA.

2022-02-10 | GSE193667 | GEO

Next Generation Sequencing Facilitates Transcriptomes Quantitative Analysis of HEK293T cells transfected with the plasmids respectively encoding RfxCas13d, crRNA and NeuN.

Project description:To determine what effect the collateral activity of RfxCas13d has on HEK293T cells upon targeting overexpressed NeuN. The plasmids encoding RfxCas13d, NeuN and NT/targeting crRNA into HEK293T cells. After 24 hours of transfection, cells were collected and extracted for total RNA. Then, we performed RNA-seq to compare the differentially expressed genes between cells transfected with targeting crRNAs and non-targeting crRNA.

2023-01-14 | GSE222451 | GEO

Next Generation Sequencing Facilitates Transcriptomes Quantitative Analysis of N2A cells transfected with the plasmids respectively encoding RfxCas13d/dRfxCas13d and crRNA.

Project description:To determine what effect the collateral activity of RfxCas13d has on N2acells. The plasmids encoding RfxCas13d/dRfxCas13d and crRNA were transfected into N2a cells. After 48 hours of transfection, GFP-positive cells were collected using FCAS and extracted for total RNA. Then, we analyzed the transcriptome of each group with RNA-seq and analyzed the differential genes among the groups.

2023-01-14 | GSE222461 | GEO